In a breakthrough discovery, scientists have uncovered a rare genetic cause of intellectual disability in an overlooked region of the human genome known as non-coding DNA. This knowledge opens up new avenues for diagnosing specific patients with these disorders.
Merck unveils the Aptegra™ CHO genetic stability assay, a groundbreaking technology that revolutionizes biosafety testing in the pharmaceutical industry. By employing whole genome sequencing and bioinformatics, Aptegra™ accelerates biosafety evaluation, enabling faster delivery of new therapies to patients.
